Titan Medical Inc. Adds Leading Robotic Surgeon Dr. John R. Valvo to Its Medical Advisory Board Bringing Both Clinical and Operating Room Experience Using Robotic Surgery Technologies
TORONTO, ONTARIO -- (MARKET WIRE) -- 08/10/10 -- Titan Medical Inc. ("the Company") (TSX VENTURE: TMD) is pleased to announce today that it has appointed Dr. John R. Valvo, M.D., F.A.C.S., to its Medical Advisory Board.
Dr. John R. Valvo, M.D., F.A.C.S. is currently the Chief of Urology and Director of Robotics at Rochester General Hospital in Rochester, New York. Following a 20 year career in performing open surgery Dr. Valvo founded the robotic program at Rochester General Hospital in early 2004, which currently ranks in the top 4% of robotic surgeries in the United States, having over 30 robotic surgeons and over 3,000 robotic surgeries performed. In addition to being an exemplary mentor to many attending physicians and residents, authoring more than 100 scientific articles and starting many robotic programs in the northeast, Dr. Valvo's focus on robotic surgery credentialing has led to a notable published paper on policy guidelines for robotic surgery. This publication has become a template for many upstart robotic surgery programs throughout the country. He has a keen interest and unique talent in performing complex urologic surgery for cancers of the genitourinary tract through the surgical platform. Dr. Valvo earned his Bachelor of Science at Marietta College and his M.D. from SUNY Buffalo. He is a fellow of the American College of Surgeons and American Urological association and is board certified by the American Board of Urology. He is also a member of the Monroe County Medical Society, Minimally Invasive Robotic Association, and Society for Lap Endoscopic Surgeons.
Dr. Reiza Rayman, President of Titan Medical Inc., commented as follows:
"We are extremely pleased to have Dr. Valvo join our Medical Advisory Board. His pioneering initiatives, expertise and in-depth understanding of robotic surgery and building robotic surgery programs in hospitals will be a great asset in the development of Amadeus, our next generation robotic surgery system."
Dr. John Valvo commented, "I am excited to join the Medical Advisory Board of a ground-breaking company like Titan Medical. I am pleased to be part of a team of respected and notable experts in robotic surgery assisting in developing Amadeus, for use in surgeries that are not possible or difficult to perform with current robotic surgery systems."
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX VENTURE: TMD) focused on the development and commercialization of robotic surgical technologies. The Company is currently developing Amadeus, a next generation 4-armed robotic surgical system, with the objective of enabling surgeons to remotely manipulate surgical instruments. Robotic surgery has developed over the past 10 years into a proven and growing method of treatment. The global robotic surgical market size is currently estimated to be over $1 billion with potential for placement of 6,000 robotic surgical systems. The Company is researching and developing innovative technologies to empower surgeons to use robots in the operating room of the future. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Filing Statement dated April 9, 2010 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Titan Medical Inc. Craig Leon Chief Executive Officer (416) 548-7522 (ext.151) info@titanmedicalinc.com www.titanmedicalinc.com
Released August 10, 2010